HK Stock Market Move | LEADS BIOLABS-B(09887) increased by over 13%, multiple research results from ESMO were selected, and the core pipeline LBL-024 was included in priority review.

LEADS BIOLABS-B (09887) rose by more than 9%, as of the time of publication, it had risen by 13.28% to 67.4 Hong Kong dollars, with a turnover of 93.3961 million Hong Kong dollars. On the news front, Vlit Corp announced that six of its latest research results had been selected for the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. Among the six selected studies, two were selected for the highest level of oral presentations, and four for poster presentations, covering the treatment areas of extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer (BTC), and relapsed/refractory multiple myeloma (RRMM). In addition, the company has been granted eligibility for a Late-Breaking Abstract (LBA) and will submit a complete LBA in September 2026. The company had previously announced that LBL-024 had been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) in September this year. On July 10th, Vlit Corp announced that the biologic product Vlezin (LBL-024), a PD-L1/4-1BB bispecific antibody developed independently by the company, for the monotherapy of advanced treated extrapulmonary neuroendocrine carcinoma (EP-NEC), had received approval to enter the priority review and approval process by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). The company stated that this milestone marks the official commercialization timeline for Vlezin being locked in, with a clear expected approval date. At the same time, Vlit Corp is actively advancing various commercialization preparations before the market launch.